| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA832: Relugolix with oestradiol and norethisterone acetate for treating uterine fibroids |
|
Medicine details |
|
| Medicine name | relugolix / estradiol / norethisterone acetate (Ryeqo®) |
| Formulation | 0.5 mg, 1 mg, 40 mg film-coated tablet |
| Reference number | 3641 |
| Indication | Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. Maintains bone mineral density and protects the uterus from endometrial hyperplasia in women who choose to use relugolix for uterine fibroid treatment |
| Company | Gedeon Richter (UK) Ltd |
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 14/06/2021 |
| NICE guidance | TA832: Relugolix with oestradiol and norethisterone acetate for treating uterine fibroids |